Advice

following an abbreviated submission:

empagliflozin/linagliptin (Glyxambi®) is accepted for restricted use within NHSScotland.

Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus:

  • To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control
  • When already being treated with the free combination of empagliflozin and linagliptin

SMC restriction: Restricted to use in line with the previous SMC advice on empagliflozin and linagliptin.

In patients for whom this combination is appropriate, empagliflozin/linagliptin (Glyxambi®) offers a single tablet at a lower cost per dose compared with the individual components.

Download detailed advice163KB (PDF)

Download

Medicine details

Medicine name:
empaglifozin linagliptin fixed-dose combination (Glyxambi)
SMC ID:
SMC1236/17
Indication:

Indicated in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control when already being treated with the free combination of empagliflozin and linagliptin

Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Endocrine system
Submission type
Abbreviated
Status
Restricted
Date advice published:
12 August 2019